Oral weight-loss drugs could account for a third or more of the overall GLP-1 market by 2030, a Novo Nordisk executive said ...

There’s no sign of GLP-1s slowing down anytime soon, especially now that they have the support of top-notch athletes.

Aon plc (NYSE: AON), a leading global professional services firm, today released updated findings from its multi-year study of U.S. commercial health claims data, building on its GLP-1 research first ...

So I wasn’t surprised when Williams was hit with a whole lot of “how dare you”—as Oprah Winfrey put it on the January 13 ...

Learn how GLP-1 medications support weight loss and heart health in perimenopause and postmenopause, plus get tips for ...

Weight loss drugs have shown impressive short-term results, but new research suggests their benefits may be difficult to ...

In a phase IIIb trial of adults with active psoriatic arthritis (PsA) and obesity or overweight, adding the GLP-1 drug ...

The research has generated significant interest from firms in food & as consumers seek natural alternatives to GLP-1 drugs.

Oral weight-loss drugs could make up a third or more of the overall GLP-1 market by 2030, a larger percentage than the ...

Bariatric surgery is a key offering for many ASCs and gastroenterology practices, despite declines in inpatient surgical ...